Nuclear Medicine/ Radiopharmaceuticals Market worth $5.26 billion by 2023

According to the new market research report “North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT – Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) – Forecasts to 2020″, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.

Don’t miss out on business opportunities in “Radiopharmaceuticals Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=417
Early buyers will receive 10% customization on reports.

This report studies the North American Nuclear Medicine/Radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach USD 2.98 Billion by 2020 from USD 1.97 Billion in 2015, at a CAGR of 8.6%.

The North American nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country.

Based on type, the North American nuclear medicine/radiopharmaceuticals market is categorized into diagnostic and therapeutic radioisotopes. In 2015, the diagnostic segment accounts for a major share of the North American nuclear medicine/radiopharmaceuticals market. The large share can be attributed to increasing patient population, introduction of new and effective radioisotopes, and increase in awareness about nuclear medicine. The diagnostic radiopharmaceuticals market is further segmented into SPECT and PET radioisotopes. In 2015, the SPECT segment accounts for the largest share of the North American diagnostic nuclear medicine/radiopharmaceuticals market. The large share of the SPECT market can be attributed to growing cancer patient population, increasing preference for SPECT procedures, advances in SPECT radioisotopes, and cyclotron-based Tc-99m generation. The therapeutic radiopharmaceuticals market is further segmented into beta emitters, alpha emitters, and brachytherapy. In 2015, the beta emitters segment accounts for the largest share of the North American nuclear therapeutic medicine/radiopharmaceuticals market. The large share of beta emitters can be attributed to heavy funding for research on beta emitters, new therapeutic radioisotopes, and reimbursement policies in favor of using radiopharmaceuticals for cancer therapy.

Based on application, the North American nuclear medicine/radiopharmaceuticals market is segmented into SPECT, PET, and therapeutic applications. In 2015, the cardiology application accounts for the largest share of North American nuclear medicine/radiopharmaceuticals market for SPECT applications. This large share can be attributed to new hardware and software designs in SPECT, rising incidence rate of CVDs, and adoption of SPECT in new cardiac applications. The PET market is dominated by oncology applications owing to its accuracy, and preference of PET over conventional imaging. In 2015, the therapeutic market was dominated by thyroid applications. This large share of thyroid applications can be attributed to the factors such as non-invasive method for treatment, and growing incidence of thyroid cancer.

Browse and in-depth TOC on “Radiopharmaceuticals Market”
92 – Tables

60 – Figures

180 – Pages

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

On the basis of country, the market is divided into U.S. and Canada. In 2015, U.S. accounts for the largest share of the North American nuclear medicine/radiopharmaceuticals market, followed by Canada. The major factors driving market growth in the U.S. include the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer Healthcare (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=417

Comments

comments

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *